Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 3,156 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Intervention Clear all

Conditions: HIV, Heart Failure
Interventions: Exercise Intervention, Tailored Education sessions, Behavioral coaching, Mobile health support, General education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 40 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Muscle Invasive Bladder Cancer
Interventions: Durvalumab, Tremelimumab, Enfortumab Vedotin, Radical Cystectomy; Drug · Procedure
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 712 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 31
States / cities: Orange, California • Santa Monica, California • New Haven, Connecticut + 28 more

Conditions: Ovarian Cancer
Interventions: Hyperthermic intraperitoneal chemotherapy (HIPEC), Carboplatin; Procedure · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 21 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: HIV, Sexually Transmitted Infections
Interventions: Testing and linkage to care for Y/MSM, Engagement and retention for HIV-positive Y/MSM in care, Engagement and retention for HIV-negative Y/MSM in sexual health services, Stribild PEP Substudy; Other · Behavioral · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 29 Years · Male only
Enrollment: 378 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Dental Alveolus, Oral Surgical Procedures, Preprosthetic
Interventions: allograft alone, allograft with autograft; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 99 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Burns
Interventions: ReCell Treatment, Skin Graft; Device · Procedure
Lead sponsor: Avita Medical; Industry
Eligibility: 5 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 7
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Tampa, Florida + 4 more

Conditions: Spinal Cord Injuries
Interventions: Seated control (CON), Moderate intensity continuous (MICT), High intensity interval training (HIIT), Circuit resistance training (CRT), Liquid Meal; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: HIV Infections
Interventions: Single dose of Genvoya® and a single 800 mg dose of Darunavir®; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine; Biological · Drug · Other
Lead sponsor: Jennifer Woyach; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Germinal Center B-cell Type (GCB)
Interventions: Rituximab, Etoposide, Copanlisib, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, ECHO, EKG, MRI Brain, 18F-FDG - PET, CT Scan, Bone Marrow Aspiration, Bone Marrow Biopsy, Lumbar Puncture (LP); Biological · Drug · Diagnostic Test + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Melanoma
Interventions: Non-Interventional; Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Morristown, New Jersey

Conditions: Type 1 Diabetes, Adolescent Behavior
Interventions: Mind-body skills, Diabetes education; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 15 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Indianapolis, Indiana

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Oxaliplatin, Pembrolizumab, Propranolol Hydrochloride, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Durvalumab, Futibatinib, Magnetic Resonance Imaging, Radical Cystectomy; Procedure · Biological · Drug
Lead sponsor: Yuanquan Yang; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio

Conditions: Violence, Cumulative Trauma, HIV Risk, Stress, Mental Health, Reproductive Health, Empowerment
Interventions: The BSHAPE Intervention; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Esophageal Squamous Cell Carcinoma
Interventions: Pembrolizumab, Lenvatinib, Cisplatin, 5-FU, Oxaliplatin, Leucovorin, Levoleucovorin, Paclitaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 863 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 15
States / cities: Duarte, California • Washington D.C., District of Columbia • Louisville, Kentucky + 10 more

Conditions: Adherence, Medication, Risk Behavior, Pre-Exposure Prophylaxis, HIV Prevention
Interventions: Emtricitabine / Tenofovir Disoproxil Oral Tablet, DOT Diary mobile app; Drug · Other
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years to 35 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 2
States / cities: San Francisco, California • Atlanta, Georgia

Conditions: Abortion, Medical
Interventions: Misoprostol-only medication abortion regimen, Combined regimen; Drug
Lead sponsor: Ibis Reproductive Health; Other
Eligibility: 14 Years and older · Female only
Enrollment: 1,900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Distress, Emotional
Interventions: Self-Efficacy, Willingness, Psychoeducation; Behavioral
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Obesity
Interventions: Standard Behavioral Treatment (SBT), Maintenance-Tailored Treatment (MTT); Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Buccal Swab, Iadademstat, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Irvine, California • Orange, California • Cincinnati, Ohio + 1 more

Conditions: PTSD, Trauma-related Mental Health Symptoms, Moral Injury, Anxiety, Traumatic Brain Injury
Interventions: stellate ganglion block with 0.5% ropivacaine; Procedure
Lead sponsor: Reset Medical and Wellness Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Strongsville, Ohio

Conditions: Cataract, IOL, Glaucoma, Open-Angle
Interventions: Cataract surgery with implantation of trifocal IOL combined with trabecular scaffold; Procedure
Lead sponsor: Vold Vision P.L.L.C; Other
Eligibility: 45 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Sub-acute Back Pain
Interventions: Naproxen, Carbidopa/Levodopa, Placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer

Connecting Resources for Urban Sexual Health

A Prospective Study: Alveolar Ridge Augmentation Using Tenting Screws, Acellular Dermal Matrix and Combination Particulate Grafts

ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

Energetic Response to Feeding and Exercise in SCI

Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States

Incorporating Mind-body Skills With Diabetes Education in Adolescents With Type 1 Diabetes

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

The BSHAPE Intervention Program for Safety and Health of Survivors of Cumulative Trauma

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).

DOT Diary Optimization Pilot: A Pilot Study to Optimize the DOT Diary App to Measure PrEP Adherence

The Misoprostol-Only Regimen Evidence Study

Targeting Components of Distress Tolerance

Maintenance-Tailored Obesity Treatment

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

Integrative Bilateral Cervical Sympathetic Blocks for Trauma-Related Symptoms in Special Operations Veterans: A Prospective Case Series

Visual Outcomes With a Trifocal IOL in Subjects With Open-angle Glaucoma

Effect of L-dopa In Subacute Back Pain Population